Dr. Patel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Blvd
Unit 0430
Houston, TX 77030Phone+1 713-792-2921Fax+1 713-745-1046- Is this information wrong?
Education & Training
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
- University of ColoradoResidency, Internal Medicine, 2005 - 2008
- University of Texas Medical Branch School of MedicineClass of 2005
Certifications & Licensure
- AZ State Medical License 2023 - 2025
- TX State Medical License 2008 - 2025
- WA State Medical License 2023 - 2025
- LA State Medical License 2023 - 2024
- TN State Medical License 2023 - 2024
- MS State Medical License 2023 - 2024
- GA State Medical License 2023 - 2024
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Start of enrollment: 2011 Dec 01
- PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy Start of enrollment: 2011 Aug 01
- Doxycycline, Temozolomide and Ipilimumab in Melanoma Start of enrollment: 2012 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- Utility of next-generation sequencing in the diagnosis of metastatic melanoma: A case report.Carlos A Torres-Cabala, Saul Turcios Escobar, Richard Yang, Kelly C Nelson, Jeffrey E Gershenwald, Hussein Tawbi, Phyu P Aung, Sapna P Patel> ;Journal of Cutaneous Pathology. 2024 May 16
- Keratosis Pilaris-Like Reaction Associated With Chromatin Remodeling Complex Inhibition in Uveal Melanoma.Madison M Taylor, Victor G Prieto, Riyad N H Seervai, Ziba Rahbar, Sapna P Patel, Kelly C Nelson, Jonathan L Curry> ;JAMA Dermatology. 2024 May 8
- Author Correction: Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.Isabella C Glitza Oliva, Sherise D Ferguson, Roland Bassett Jr, Alexandra P Foster, Ida John, Tarin D Hennegan, Michelle Rohlfs, Jessie Richard, Masood Iqbal, Tina Det...> ;Nature Medicine. 2024 Apr 22
- Join now to see all
Journal Articles
- Publisher Correction: Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable MelanomaScott Woodman, Alexander J Lazar, Michael A Davies, Neil Gross, Sapna P Patel, Isabella C Glitza, Ehab Hanna, Stephen Y Lai, Richard Ehlers, Amy Hessel, Padmanee Sharm..., Nature
- Author Correction: Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable MelanomaJanice N Cormier, Ehab Hanna, Padmanee Sharma, Jennifer A Wargo, Isabella C Glitza, Sapna P Patel, Adi Diab, Jeffrey E Lee, Richard Royal, Randal Weber, Patrick Hwu, J..., Nature
- Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable MelanomaRichard Royal, Alexander J Lazar, Adi Diab, Sapna P Patel, Jeffrey E Lee, Padmanee Sharma, Patrick Hwu, Randal Weber, Jeffrey Gershenwald, Carol Lewis, Richard Ehlers,..., Nature
Press Mentions
- Melanoma Survivor: Protect Your SkinMarch 19th, 2019
- Pembrolizumab Trial in Advanced Melanoma Shows Major Pathological Response Exceeding 50%October 25th, 2023
- Major Pathologic Response to Neoadjuvant Pembrolizumab in Advanced Melanoma Trial Exceeds 50%October 25th, 2023
Hospital Affiliations
- University of Texas M.D. Anderson Cancer CenterHouston, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: